Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TTFields) at the American Society for Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24 through September 27 in San Diego. A late-breaking oral presentation will focus on Novocure’s EF-14 phase 3 pivotal trial. This marks the first presentation of EF-14 five-year survival and quality of life data at a radiation oncology conference. A second oral presentation will highlight new preclinical data on the effects of TTFields in delaying DNA damage repair following radiation treatment of glioma cells.
“We are excited to have a variety of research on TTFields presented at ASTRO’s 2017 Annual Meeting,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “Radiation oncologists are our second largest community of treating physicians for Optune. We appreciate the opportunity to continue our dialogue through the exchange of scientific information at the premier meeting for radiation oncologists.”
The following will be presented at the ASTRO 2017 Annual Meeting:
Late-breaking oral presentation
(LBA-6) Tumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life. R. Stupp. 3:15 – 4:15 p.m. PST on Sunday, September 24. (Location: Ballroom 20)
(68) Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation through TTFields Transducer Arrays. M. Story. 7:45 to 9 a.m. PST on Monday, September 25. (Location: Room 4)
(3530) Creating patient-specific computational head models for the study of tissue-electric field interactions using deformable templates. N. Urman. 4:15 to 5:45 p.m. PST on Monday, September 25. (Location: Poster Hall)
(3529) Measuring the electric properties of human skin in order to understand how Tumor Treating Fields distribute within the body. H. Hershkovich. 4:15 to 5:45 p.m. PST on Monday, September 25. (Location: Poster Hall)
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investors:
Ashley Cordova, 212-767-7558